297 related articles for article (PubMed ID: 26461819)
21. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
[TBL] [Abstract][Full Text] [Related]
22. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
Frampton JE
Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
[TBL] [Abstract][Full Text] [Related]
23. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
24. Risankizumab (Skyrizi) for psoriasis.
Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
[No Abstract] [Full Text] [Related]
25. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
26. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
Yiu ZZ; Warren RB
Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
[TBL] [Abstract][Full Text] [Related]
27. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
28. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
Gordon KB; Langley RG; Gottlieb AB; Papp KA; Krueger GG; Strober BE; Williams DA; Gu Y; Valdes JM
J Invest Dermatol; 2012 Feb; 132(2):304-14. PubMed ID: 22011907
[TBL] [Abstract][Full Text] [Related]
29. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
30. Guselkumab for the treatment of psoriasis.
Megna M; Balato A; Raimondo A; Balato N
Expert Opin Biol Ther; 2018 Apr; 18(4):459-468. PubMed ID: 29482382
[TBL] [Abstract][Full Text] [Related]
31. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.
Yang EJ; Smith MP; Ly K; Bhutani T
Drug Des Devel Ther; 2019; 13():1993-2000. PubMed ID: 31354244
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
33. Brodalumab: A Review of Safety.
Rusta-Sallehy S; Gooderham M; Papp K
Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
[TBL] [Abstract][Full Text] [Related]
34. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
35. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
[TBL] [Abstract][Full Text] [Related]
36. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
Howell ST; Cardwell LA; Feldman SR
Ann Pharmacother; 2018 Apr; 52(4):380-387. PubMed ID: 29134822
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.
No DJ; Amin M; Bhutani T; Wu JJ
J Dermatolog Treat; 2018 Aug; 29(5):467-474. PubMed ID: 29103334
[TBL] [Abstract][Full Text] [Related]
38. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
39. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
Scanlon JV; Exter BP; Steinberg M; Jarvis CI
Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
[TBL] [Abstract][Full Text] [Related]
40. Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies.
Zhang TT; Ma J; Durbin KR; Montavon T; Lacy SE; Jenkins GJ; Doktor S; Kalvass JC
AAPS J; 2019 Jun; 21(5):82. PubMed ID: 31250228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]